Pfizer DTC Comments Prescribe Limited Risk Info, Reliance On Physicians
Executive Summary
Risk information in direct-to-consumer ads should be designed to prompt more patient-physician dialogue, Pfizer suggested in comments to FDA
You may also be interested in...
Print Ads Should Use Limited “Brief Summary” Like TV Spots, FTC Tells FDA
The Federal Trade Commission is encouraging FDA to ease its requirements for direct-to-consumer print advertisements and allow them to include a more limited "brief summary" like TV ads do
DTC Effect On Patient Benefit, Compliance Needs More Study – FDA’s Temple
The effect of direct-to-consumer advertising on patient behavior needs to be further studied, FDA Center for Drug Evaluation & Research Office of Medical Policy Director Robert Temple, MD, suggested
DTC Risk Information Placement Can Affect Fair Balance, Academic Tells FDA
Direct-to-consumer ads need to better reflect the effect of risk information placement on patient comprehension of a drug's risk-benefit profile, a Duke University professor told FDA during a public meeting on DTC advertising in Washington, D.C. Sept. 22